Geode Capital Management
VIRX

Geode Capital Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Geode Capital Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-224,250
Closed -$36.1K – 4555
2024
Q4 		$36.1K Sell
224,250
-25,757
-10% -$5.07K ﹤0.01% 4295
2024
Q3 		$57.9K Sell
250,007
-20,766
-8% -$7.62K ﹤0.01% 4232
2024
Q2 		$147K Buy
270,773
+18,072
+7% +$14.3K ﹤0.01% 4018
2024
Q1 		$258K Hold
252,701
– – ﹤0.01% 3854
2023
Q4 		$144K Hold
252,701
– – ﹤0.01% 4054
2023
Q3 		$263K Buy
252,701
+28,263
+13% +$38.4K ﹤0.01% 3869
2023
Q2 		$316K Hold
224,438
– – ﹤0.01% 3831
2023
Q1 		$357K Hold
224,438
– – ﹤0.01% 3781
2022
Q4 		$327K Buy
224,438
+6,502
+3% +$19K ﹤0.01% 3854
2022
Q3 		$930K Buy
217,936
+14,304
+7% +$60.6K ﹤0.01% 3422
2022
Q2 		$790K Sell
203,632
-278,093
-58% -$792K ﹤0.01% 3526
2022
Q1 		$2.29M Buy
481,725
+20,498
+4% +$61.8K ﹤0.01% 3193
2021
Q4 		$1.68M Sell
461,227
-20,074
-4% -$107K ﹤0.01% 3459
2021
Q3 		$3.86M Buy
481,301
+32,065
+7% +$316K ﹤0.01% 3062
2021
Q2 		$5.09M Buy
449,236
+390,701
+667% +$3.92M ﹤0.01% 2897
2021
Q1 		$541K Buy
58,535
+34,663
+145% +$361K ﹤0.01% 3775
2020
Q4 		$166K Buy
23,872
+5,679
+31% +$29.6K ﹤0.01% 3933
2020
Q3 		$79K Sell
18,193
-1
-0% -$9 ﹤0.01% 3951
2020
Q2 		$167K Hold
18,194
– – ﹤0.01% 3706
2020
Q1 		$264K Buy
18,194
+118
+0.7% +$2.56K ﹤0.01% 3467
2019
Q4 		$213K Buy
18,076
+484
+3% +$8.1K ﹤0.01% 3773
2019
Q3 		$443K Buy
17,592
+3,921
+29% +$113K ﹤0.01% 3510
2019
Q2 		$347K Buy
13,671
+4,672
+52% +$181K ﹤0.01% 3592
2019
Q1 		$382K Buy
8,999
+4,345
+93% +$98.4K ﹤0.01% 3539
2018
Q4 		$67K Hold
4,654
– – ﹤0.01% 3940
2018
Q3 		$325K Buy
4,654
+367
+9% +$27.9K ﹤0.01% 3596
2018
Q2 		$318K Buy
4,287
+367
+9% +$32.7K ﹤0.01% 3577
2018
Q1 		$373K Buy
3,920
+335
+9% +$57.5K ﹤0.01% 3497
2017
Q4 		$463K Buy
3,585
+1,838
+105% +$172K ﹤0.01% 3382
2017
Q3 		$118K Hold
1,747
– – ﹤0.01% 3792
2017
Q2 		$165K Sell
1,747
-35
-2% -$4.02K ﹤0.01% 3744
2017
Q1 		$255K Buy
1,782
+160
+10% +$22.9K ﹤0.01% 3566
2016
Q4 		$205K Buy
1,622
+3
+0.2% +$418 ﹤0.01% 3615
2016
Q3 		$247K Hold
1,619
– – ﹤0.01% 3525
2016
Q2 		$186K Hold
1,619
– – ﹤0.01% 3617
2016
Q1 		$183 Hold
1,619
– – ﹤0.01% 3661
2015
Q4 		$305K Buy
1,619
+1
+0.1% +$187 ﹤0.01% 3501
2015
Q3 		$275K Buy
1,618
+417
+35% +$150K ﹤0.01% 3528
2015
Q2 		$759K Buy
1,201
+6
+0.5% +$3.19K ﹤0.01% 3029
2015
Q1 		$614K Buy
1,195
+69
+6% +$34.8K ﹤0.01% 3106
2014
Q4 		$603K Buy
1,126
+119
+12% +$53.6K ﹤0.01% 3102
2014
Q3 		$1.51M Buy
1,007
+88
+10% +$127K ﹤0.01% 2536
2014
Q2 		$1.26M Buy
919
+59
+7% +$68.5K ﹤0.01% 2654
2014
Q1 		$1.19M Buy
860
+178
+26% +$207K ﹤0.01% 2668
2013
Q4 		$679K Buy
682
+10
+1% +$10.3K ﹤0.01% 2930
2013
Q3 		$700K Buy
672
+21
+3% +$22.4K ﹤0.01% 2779
2013
Q2 		$713K Buy
+651
New +$725K ﹤0.01% 2660

Other funds holding VIRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Geode Capital Management's VIRX Position: Q1 2025 in Review

Geode Capital Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2025, closing a stake of 224,250 shares — an estimated $36.1K sold.

Geode Capital Management first reported a position in VIRX in Q2 2013 and held it in 47 quarters. The position peaked at $5.09M in Q2 2021. 7 funds tracked by Wall St. Rank hold VIRX as of Q1 2025.

  • Geode Capital Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Geode Capital Management sold 224,250 Viracta Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $36.1K.
  • Geode Capital Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 47 quarters.
  • Geode Capital Management's Viracta Therapeutics, Inc. Common Stock position peaked at $5.09M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Geode Capital Management's 13F filing for Q1 2025, filed 13 May 2025.